{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:34:03Z","timestamp":1791952443348,"version":"4.3.4"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Melioidosis is an infectious disease with a propensity for relapse, despite prolonged antibiotic eradication therapy for 12 to 20 weeks. A pharmacokinetic (PK) simulation study was performed to determine the optimal dosing of cotrimoxazole (trimethoprim-sulfamethoxazole [TMP-SMX]) used in current eradication regimens in Thailand and Australia. Data for bioavailability, protein binding, and coefficients of absorption and elimination were taken from published literature. Apparent volumes of distribution were correlated with body mass and were estimated separately for Thai and Australian populations. In vitro experiments demonstrated concentration-dependent killing. In Australia, the currently used eradication regimen (320 [TMP]\/1,600 [SMX] mg every 12 h [q12h]) was predicted to achieve the PK-pharmacodynamic (PD) target (an area under the concentration-time curve from 0 to 24 h\/MIC ratio of &gt;25 for both TMP and SMX) for strains with the MIC\n                    <jats:sub>90<\/jats:sub>\n                    of Australian strains (\u22641\/19 mg\/liter). In Thailand, the former regimen of 160\/800 mg q12h would not be expected to attain the target for strains with an MIC of \u22651\/19 mg\/liter, but the recently implemented weight-based regimen (&lt;40 kg [body weight], 160\/800 mg q12h; 40 to 60 kg, 240\/1,200 mg q12h; &gt;60 kg, 320\/1,600 mg q12h) would be expected to achieve adequate concentrations for strains with an MIC of \u22641\/19 mg\/liter. The results were sensitive to the variance of the PK parameters. Prospective PK-PD studies of Asian populations are needed to optimize TMP-SMX dosing in melioidosis.\n                  <\/jats:p>","DOI":"10.1128\/aac.01301-08","type":"journal-article","created":{"date-parts":[[2009,7,20]],"date-time":"2009-07-20T20:58:33Z","timestamp":1248123513000},"page":"4193-4199","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":53,"title":["Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis"],"prefix":"10.1128","volume":"53","author":[{"given":"Allen C.","family":"Cheng","sequence":"first","affiliation":[{"name":"Menzies School of Health Research, Charles Darwin University, Darwin, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S.","family":"McBryde","sequence":"additional","affiliation":[{"name":"Victorian Infectious Diseases Service, Royal Melbourne Hospital, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanaporn","family":"Wuthiekanun","sequence":"additional","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wirongrong","family":"Chierakul","sequence":"additional","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premjit","family":"Amornchai","sequence":"additional","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P. J.","family":"Day","sequence":"additional","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"},{"name":"Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"},{"name":"Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J.","family":"Peacock","sequence":"additional","affiliation":[{"name":"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand"},{"name":"Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"4802.0-National Nutrition Survey 1997"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.24.9.798"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4020-4025.2005"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/520218"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.5.1181"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.2.383-416.2005"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl389"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199603000-00015"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(00)90333-X"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/318116"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/24.3.295"},{"key":"e_1_3_3_13_2","first-page":"311","volume":"24","year":"1989","unstructured":"Dance, D. A., V. Wuthiekanun, W. Chaowagul, and N. J. White. 1989. Interactions in vitro between agents used to treat melioidosis. J. Antimicrob. Chemother.24:311-316.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_3_14_2","unstructured":"Health Survey for England 1995. 1997"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00334-4"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1974.tb02300.x"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/507632"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.12.6032-6034.2005"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000221272"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198005050-00001"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(02)00016-X"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2005.82"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0035-9203(95)90104-3"},{"key":"e_1_3_3_24_2","first-page":"S330","volume":"4","year":"1979","unstructured":"Reeves, D. S., and P. J. Wilkinson. 1979. The pharmacokinetics of trimethoprim and trimethoprim\/sulphonamide combinations, including penetration into body tissues. Infection4(7 Suppl.):S330-S341.","journal-title":"Infection"},{"key":"e_1_3_3_25_2","first-page":"148","volume":"18","year":"1974","unstructured":"Rieder, J., D. E. Schwartz, M. Fernex, T. Bergan, E. K. Brodwall, A. Blumberg, P. Cottier, and W. Scheitlin. 1974. Pharmacokinetics of the antibacterial combination sulfamethoxazole plus trimethoprim in patients with normal or impaired kidney function. Antibiot. Chemother.18:148-198.","journal-title":"Antibiot. Chemother."},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1159\/000220701"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/520223"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb05114.x"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.2000"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/128.Supplement_3.S556"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki151"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01301-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01301-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T14:49:03Z","timestamp":1645454943000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01301-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1128\/AAC.01301-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.01301-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"2008-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-07-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}